Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Myelofibrosis Treatment Market: By Drug Type: Hydroxyurea, Immunomodulators, JAK Inhibitor, Others; By Treatment Type: Blood Transfusion, Chemotherapy, Androgen Therapy, Others; By End Use; Regional Analysis; Historical Market and Forecast (2015-2025); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Myelofibrosis Treatment Market Outlook

The global myelofibrosis treatment market to be aided by the growth of the blood and bone marrow cancer treatment market. The global blood and bone marrow cancer treatment market is projected to grow at a CAGR of 7% in the forecast period of 2020-2025.

 

Myelofibrosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Growing Awareness Regarding Chemotherapy to Aid the Myelofibrosis Treatment Industry

Based on treatment type, the chemotherapy segment holds a significant share in the global myelofibrosis treatment industry. The growth of the segment can be attributed to the easy availability of agents required for chemotherapy and the approval of Ruxolitinib (Jakafi) by the US Food and Drug Administration. It is a JAK1 and JAK2 inhibitor that targets overactive JAK pathway signalling, which plays a major role in the development of myelofibrosis. Currently, Ruxolitinib is the only FDA-approved chemotherapeutic agent for the treatment of myelofibrosis, which is driving the demand for this drug and aiding the growth of the segment.

 

North America to Significantly Contribute to the Myelofibrosis Treatment Industry Expansion

The global market for myelofibrosis treatment is expected to be dominated by the North America region. The demand is growing in the region due to the availability of advanced healthcare facilities and increased awareness regarding the treatment of cancer. The favourable government initiatives and the growing number of clinical trials in the region are also aiding the industry growth. The Asia Pacific is expected to provide enhanced growth opportunities for the market expansion over the forecast period owing to the presence of a large population and improving healthcare facilities in the region.

 

Myelofibrosis Treatment Market by Drug Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Myelofibrosis Treatment: Industry Definition and Segmentation

Myelofibrosis (MF), a rare disease, is a type of blood disorder called myeloproliferative neoplasm. All myeloproliferative neoplasms are classed as blood cancers by the World Health Organisation (WHO). In people with myelofibrosis, the scar tissue builds up inside the bone marrow due to which blood cells do not develop properly. The condition causes extensive scarring in bone marrow, leading to severe anaemia that can cause weakness and fatigue. A normal blood test, along with bone marrow biopsy, can help diagnose myelofibrosis in a person.

Based on drug type, the market is divided into:

  • Hydroxyurea
  • Immunomodulators
  • JAK Inhibitor
  • Others

Based on treatment type, the industry can be segmented into:

  • Blood Transfusion
  • Chemotherapy
  • Androgen Therapy
  • Stem Cell/Bone Marrow Transplantation
  • Others

The major end-use sectors of the product include:

  • Hospitals
  • Clinics
  • Bone Marrow Transplant Centres
  • Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Myelofibrosis Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Growing R&D Activities and New Drug Approvals to Augment the Growth of the Myelofibrosis Treatment Industry

The unmet needs of the patients suffering from myelofibrosis are pushing manufacturers to innovate new solutions. The growing investments in the research and development activities to develop a specific treatment for myelofibrosis is expected to bolster the growth of the industry in the forecast period. The rapid advancements in technology and the ongoing clinical trials are contributing to the industry growth. Other factors like improved reimbursement policies, favourable government initiatives, growing healthcare sector, busy lifestyle and changing dietary patterns, increase in smoking population, and growing incidence of genetic disorders are also contributing to the industry growth. However, limited awareness and high costs involved in treatment might hamper the growth of the industry in the coming years.

 

Key Industry Players in the Global Myelofibrosis Treatment Market

The report gives a detailed analysis of the following key players in the global myelofibrosis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Incyte Corporation
  • Novartis AG
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Myelofibrosis Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Myelofibrosis Treatment Historical Market (2015-2019) 
    8.3    Global Myelofibrosis Treatment Market Forecast (2020-2025)
    8.4    Global Myelofibrosis Treatment Market by Drug Type 
        8.4.1    Hydroxyurea
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2015-2019)
            8.4.1.3    Forecast Trend (2020-2025)
        8.4.2    Immunomodulators
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2015-2019)
            8.4.2.3    Forecast Trend (2020-2025)
        8.4.3    JAK Inhibitor
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2015-2019)
            8.4.3.3    Forecast Trend (2020-2025)
        8.4.4    Others
    8.5    Global Myelofibrosis Treatment Market by Treatment Type
        8.5.1    Blood Transfusion
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2015-2019)
            8.5.1.3    Forecast Trend (2020-2025)
        8.5.2    Chemotherapy
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2015-2019)
            8.5.2.3    Forecast Trend (2020-2025)
        8.5.3    Androgen Therapy
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2015-2019)
            8.5.3.3    Forecast Trend (2020-2025)
        8.5.4    Stem Cell/Bone Marrow Transplantation
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2015-2019)
            8.5.4.3    Forecast Trend (2020-2025)
        8.5.5    Others
    8.6    Global Myelofibrosis Treatment Market by End Use
        8.6.1    Hospitals
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2015-2019)
            8.6.1.3    Forecast Trend (2020-2025)
        8.6.2    Clinics
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2015-2019)
            8.6.2.3    Forecast Trend (2020-2025)
        8.6.3    Bone Marrow Transplant Centers
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2015-2019)
            8.6.3.3    Forecast Trend (2020-2025)
        8.6.4    Others
    8.7    Global Myelofibrosis Treatment Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2015-2019)
        9.1.2    Forecast Trend (2020-2025)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2015-2019)
        9.2.2    Forecast Trend (2020-2025)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2015-2019)
        9.3.2    Forecast Trend (2020-2025)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2015-2019)
        9.4.2    Forecast Trend (2020-2025)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2015-2019)
        9.5.2    Forecast Trend (2020-2025)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Incyte Corporation
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Novartis AG
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Celgene Corporation
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Eli Lilly and Company
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Gilead Sciences, Inc.
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments

 

Additional Customisations Available

1    Manufacturing Process
    1.1    Overview
    1.2    Detailed Process Flow
    1.3    Operation Involved
2    Project Requirements and Cost Analysis
    2.1    Land, Location, and Site Development
    2.2    Construction
    2.3    Plant Machinery
    2.4    Cost of Raw Material
    2.5    Packaging
    2.6    Transportation
    2.7    Utilities
    2.8    Manpower
    2.9    Other Capital Investments

 

List of Figures and Tables

1.    Global Myelofibrosis Treatment Market: Key Industry Highlights, 2015 and 2025
2.    Global Myelofibrosis Treatment Historical Market: Breakup by Drug Type (USD Billion), 2015-2019
3.    Global Myelofibrosis Treatment Market Forecast: Breakup by Drug Type (USD Billion), 2020-2025
4.    Global Myelofibrosis Treatment Historical Market: Breakup by Treatment Type (USD Billion), 2015-2019
5.    Global Myelofibrosis Treatment Market Forecast: Breakup by Treatment Type (USD Billion), 2020-2025
6.    Global Myelofibrosis Treatment Historical Market: Breakup by End Use (USD Billion), 2015-2019
7.    Global Myelofibrosis Treatment Market Forecast: Breakup by End Use (USD Billion), 2020-2025
8.    Global Myelofibrosis Treatment Historical Market: Breakup by Region (USD Billion), 2015-2019
9.    Global Myelofibrosis Treatment Market Forecast: Breakup by Region (USD Billion), 2020-2025
10.    North America Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2015-2019
11.    North America Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2020-2025
12.    Europe Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2015-2019
13.    Europe Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2020-2025
14.    Asia Pacific Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2015-2019
15.    Asia Pacific Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2020-2025
16.    Latin America Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2015-2019
17.    Latin America Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2020-2025
18.    Middle East and Africa Myelofibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2015-2019
19.    Middle East and Africa Myelofibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2020-2025
20.    Global Myelofibrosis Treatment Market Structure

Key Questions Answered in the Report

The global myelofibrosis treatment market is being driven by the blood and bone marrow cancer treatment market, which is projected to grow at a CAGR of 7% between 2020 and 2025.

The major drivers of the industry, such as rising disposable incomes, increasing population, the easy availability of agents required for chemotherapy, the approval of Ruxolitinib (Jakafi) by the US Food and Drug Administration, implementation of favourable government initiatives, improving healthcare facilities, and the rising number of clinical trials, are expected to aid the market growth.

The key trends guiding the growth of the market include the rising investments in the research and development activities and rising advancements in technology.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major drug types in the market are hydroxyurea, immunomodulators, and JAK inhibitor, among others.

The leading treatment types in the industry are blood transfusion, chemotherapy, androgen therapy, and stem cell/bone marrow transplantation, among others.

The significant end-use sectors in the market are hospitals, clinics, and bone marrow transplant centres, among others.

The major players in the industry are Incyte Corporation, Novartis AG, Celgene Corporation, Eli Lilly and Company, and Gilead Sciences, Inc., among others.

Analyst Review

The global myelofibrosis treatment market is being driven by the rising implementation of favourable government policies. The market is being aided by the global blood and bone marrow cancer treatment market, which is expected to grow at a CAGR of 7% between 2020 and 2025.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By drug type, the market is segmented into hydroxyurea, immunomodulators, and JAK inhibitor, among others. On the basis of treatment type, the industry is divided into blood transfusion, chemotherapy, androgen therapy, and stem cell/bone marrow transplantation, among others. Based on end-uses, the market is categorised into hospitals, clinics, and bone marrow transplant centres, among others. The major regional markets for myelofibrosis treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Incyte Corporation, Novartis AG, Celgene Corporation, Eli Lilly and Company, and Gilead Sciences, Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 1099     $999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Single User License

$ 2999     $1999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Five User License

$ 3999     $2999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Corporate License

$ 4999     $3999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports

Global Non-Union Fractures Market Report and Forecast 2020-2025


Global Shock Wave Therapy Device Market Report and Forecast 2020-2025


Global Hyperoxemia Treatment Market Report and Forecast 2020-2025


Global Chromhidrosis Treatment Market Report and Forecast 2020-2025


NEWSLETTER